Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DXR vs ELMD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DXR Captures Overall Composite Edge (52.2 HOLD vs 41.1 SELL), While ELMD Leads 4–2 on Growth & Valuation Pillars

DXR Overall Winner 6-Pillar Tally: DXR 2 – 4 ELMD Matrix Metrics: DXR 5 – 4 ELMD

As of Nov 16, 2026, Daxor Corporation (DXR) captures the overall head-to-head institutional edge over Electromed, Inc. (ELMD) on higher Unified Composite conviction (52.2/100 HOLD vs. 41.1/100 SELL) after splitting the core matrix 5–4 (led by Growth & Scale, Options & Positioning), while ELMD wins 4–2 across the 6-pillar growth and valuation breakdown. DXR trades at $8.36 (64.5x Forward P/E, -5894.3% operating margin) versus ELMD at $23.10 (15.6x Forward P/E, 19.4% operating margin).

  • Growth vs. Quality Trade-Off: DXR earns the overall head-to-head edge with a stronger Unified Composite Score (52.2/100 HOLD vs. ELMD 41.1/100 SELL) and 0.28β · 32% Vol risk profile, whereas ELMD leads top-line expansion (+10.6% YoY revenue growth, 0.35x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: DXR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2); meanwhile ELMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DXR vs ELMD
DXR NASDAQ Head-to-Head Winner
Daxor Corporation Common Stock
Surgical & Medical Instruments & Apparatus
$8.36
-1.47% 1D
Market Cap $49.5M
TTM Revenue $31,360
Forward P/E 64.5x
Beta / 30D Vol 0.28β · 32% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 52.0 Fund 59.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.2%), weak momentum, RSI 31
RSI-14: 31.2 · SMA20: $8.91 · SMA50: $10.07
ELMD NYSE American
Electromed, Inc.
Electromedical & Electrotherapeutic Apparatus
$23.10
-5.02% 1D
Market Cap $198.8M
TTM Revenue $76M
Forward P/E 15.6x
Beta / 30D Vol 0.76β · 45% Vol
Unified Composite Score
41.1 / 100 SELL
Tech 25.0 Fund 45.0 Flow 60.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -12.5%), weak momentum, RSI 25
RSI-14: 25.3 · SMA20: $26.52 · SMA50: $27.12

6-Pillar Scorecard Institutional Category Breakdown (DXR 2 – 4 ELMD)

Columns: Metric · DXR · ELMD
1. Valuation Multiples ELMD
Forward P/E 64.5x 15.6x
Trailing P/E 7.7x 17.6x
PEG Ratio N/M 0.35x
EV / Revenue N/M 2.6x
2. Growth & Scale DXR
Revenue Growth (YoY) +25.5% +10.6%
Earnings Growth (YoY) +329.3% +28.0%
TTM Revenue (USD) $31,360 $76M
Market Cap $49.5M $198.8M
3. Profitability & Quality ELMD
Gross Margin 100.0% 79.0%
Operating Margin -5894.3% 19.4%
Net Profit Margin 19861.4% 15.8%
Return on Equity (ROE) 14.2% 24.5%
4. Balance Sheet & Cash Flow ELMD
Cash Generation (TTM) N/A $8.6M
Cash Flow Margin N/A 11.4%
Net Cash / Leverage $8.88 Book/Sh · 14.2% ROE $6.37 Book/Sh · 24.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DXR
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 43.0% (11th %ile)
Put/Call OI Skew N/A 0.23x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat ELMD
OpEx & R&D Intensity N/A 59.6% of Rev ($45M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Medical Instruments & Supplies Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DXR (5) vs ELMD (4)
Institutional Metric DXR ELMD Criterion Row Edge
Market Capitalization
Scale
$49.5M $198.8M Larger Scale ELMD
Trailing P/E Ratio
Valuation
7.7x 17.6x Lower Multiple DXR
Forward P/E Ratio
Valuation
64.5x 15.6x Lower Multiple ELMD
Revenue Growth (YoY)
Growth
+25.5% +10.6% Higher Growth DXR
Operating Margin (TTM)
Profitability
-5894.3% 19.4% Higher Margin ELMD
Net Profit Margin
Profitability
19861.4% 15.8% Higher Margin DXR
Return on Equity (ROE)
Capital Efficiency
14.2% 24.5% Higher ROE ELMD
52-Week Range Position
Momentum
2% ($8–$15) 2% ($23–$47) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
0.28β · 32% Vol 0.76β · 45% Vol Lower Realized Risk DXR
Unified Institutional Score
Composite Signal
52.2 / 100 (HOLD) 41.1 / 100 (SELL) Higher Composite DXR
Trailing 12M Revenue (USD)
Operating Scale
$31,360 $76M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% 79.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 0.35x PEG · 2.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($8.88 Book/Sh · 14.2% ROE) $8.6M ($6.37 Book/Sh · 24.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ELMD +1.12 pp
DXR: -16.87% · ELMD: -15.75%
3M Horizon DXR +26.04 pp
DXR: -19.66% · ELMD: -45.7%
6M Horizon ELMD +7.82 pp
DXR: -17.44% · ELMD: -9.62%
1Y Horizon ELMD +20.94 pp
DXR: -33.27% · ELMD: -12.33%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DXR vs ELMD. Trailing 12-month operating profitability (DXR -5894.3% vs ELMD 19.4%) and valuation multiples (DXR 64.5x vs ELMD 15.6x Forward P/E) are benchmarked directly in Pillar 4 below.

DXR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$31,360
Gross Margin100.0%
Op. Margin-5894.3%
ROE / Fwd P/E14.2% · 64.5x
ELMD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$76M
Gross Margin79.0%
Op. Margin19.4%
ROE / Fwd P/E24.5% · 15.6x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DXR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DXR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ELMD BREAKDOWN
94d in phase · OBV DISTRIBUTION
Current IV 43.0%
IV Percentile 11th %ile
Put/Call OI Skew 0.23x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact ELMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DXR Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $49.5M market capitalization and -5894.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ELMD Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $198.8M market capitalization and 19.4% operating margin.
OpEx & R&D Reinvestment 59.6% of Rev ($45M)
90D Engineering Disclosures 0 Published

Investor FAQ DXR vs ELMD Key Questions & Quantitative Answers

As of Nov 16, 2026, Daxor Corporation (DXR) captures the overall head-to-head institutional edge over Electromed, Inc. (ELMD) on higher Unified Composite conviction (52.2/100 HOLD vs. 41.1/100 SELL) after splitting the core matrix 5–4 (led by Growth & Scale, Options & Positioning), while ELMD wins 4–2 across the 6-pillar growth and valuation breakdown. DXR trades at $8.36 (64.5x Forward P/E, -5894.3% operating margin) versus ELMD at $23.10 (15.6x Forward P/E, 19.4% operating margin). Growth vs. Quality Trade-Off: DXR earns the overall head-to-head edge with a stronger Unified Composite Score (52.2/100 HOLD vs. ELMD 41.1/100 SELL) and 0.28β · 32% Vol risk profile, whereas ELMD leads top-line expansion (+10.6% YoY revenue growth, 0.35x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: DXR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2); meanwhile ELMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DXR leads the Growth & Scale pillar: DXR posts +25.5% YoY revenue growth and +329.3% YoY earnings growth on $31,360 TTM revenue (100.0% gross margin, -5894.3% operating margin), compared with ELMD at +10.6% YoY revenue growth and +28.0% YoY earnings growth on $76M TTM revenue (79.0% gross margin, 19.4% operating margin). On trailing 12-month operating scale, DXR generates $31,360 in USD-normalized revenue versus $76M for ELMD. In operating R&D and SG&A reinvestment, DXR deploys N/A (0 90-day corporate R&D disclosures) versus 59.6% of Rev ($45M) (0 disclosures) for ELMD.

ELMD screens cheaper on headline valuation multiples. DXR trades at 64.5x Forward P/E, 7.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ELMD trades at 15.6x Forward P/E, 17.6x Trailing P/E, 0.35x PEG, and 2.6x EV/Revenue (11.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DXR (14.2% ROE) versus ELMD (24.5% ROE) capital efficiency.

In options market volatility and institutional positioning, DXR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.28β · 32% Vol realized risk). By comparison, ELMD carries 43.0% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.23x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.76β · 45% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.